Engineered probiotics platform for resolvin E1 biosynthesis confers protection against inflammatory disease
Clinical and Translational Medicine · 2026
DOI: 10.1002/ctm2.70746 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2026. Verfasst von Xiaoxiao Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases & Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen Univers…. Hauptthemen laut MEDLINE: Probiotics, Eicosapentaenoic Acid, Inflammation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Key Laboratory of Systems Medicine, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Background
The resolution of inflammation is actively driven by omega‐3 polyunsaturated fatty acids (PUFAs) via their specialized pro‐resolving mediator (SPM) derivatives, including resolvin E1 (RvE1), whose role has been well established. However, clinical application of these mediators is hampered by inherent instability and elevated production costs.
Methods
To surmount these obstacles, we have engineered a biosynthetic platform based on the probiotic Escherichia coli Nissle 1917 (EcN) that enables controlled, sustained RvE1 production through inducible expression of COX2 and 5‐LOX, designated EcN‐RvE1. The catalytic capacity, intestinal persistence, and therapeutic efficacy of the platform were evaluated in vitro and in LPS‐induced acute inflammation and DSS‐induced colitis murine models.
Results
In this study, we validate the capacity of EcN‐RvE1 to catalyse the conversion of eicosapentaenoic acid (EPA) to RvE1 and confirm its ability to achieve long‐term intestinal persistence. In murine models of acute inflammation and colitis, EcN‐RvE1 exerts marked anti‐inflammatory and tissue‐protective effects, which are mediated by the regulation of inflammatory cytokine expression and the amelioration of gut microbiota dysbiosis. Moreover, EcN‐RvE1 using Euglena gracilis as a photosynthetic protist‐based source of PUFAs also exhibits protective anti‐inflammatory activity.
Conclusion
Collectively, we report a probiotic engineering platform for the biosynthesis of RvE1, offering a novel strategy for harnessing the anti‐inflammatory potential of PUFAs derivatives in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases & Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University Shenzhen Campus, Shenzhen, China.
- Department of Geriatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Xiaoxiao Li, Zewei Zhao, Zhonghan Yang
Förderung
- Shenzhen Key Laboratory of Systems Medicine
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Li, X., Lin, J., Liu, Q., Wu, Y., Wu, Q., Zhao, Z., Cai, Y., Lin, S., Zheng, Z., Chen, X., Li, J., & Yang, Z. (2026). Engineered probiotics platform for resolvin E1 biosynthesis confers protection against inflammatory disease. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70746
Vancouver
Li X, Lin J, Liu Q, Wu Y, Wu Q, Zhao Z, et al. Engineered probiotics platform for resolvin E1 biosynthesis confers protection against inflammatory disease. Clinical and Translational Medicine. 2026. doi:10.1002/ctm2.70746
BibTeX
@article{Li2026,
author = {Li, Xiaoxiao and Lin, Jiejing and Liu, Qingqing and Wu, Yiqun and Wu, Qian and Zhao, Zewei and Cai, Yi and Lin, Shengliang and Zheng, Zijie and Chen, Xinpan and Li, Jin and Yang, Zhonghan},
title = {Engineered probiotics platform for resolvin E1 biosynthesis confers protection against inflammatory disease},
journal = {Clinical and Translational Medicine},
year = {2026},
doi = {10.1002/ctm2.70746}
}
EUVIMED